EUVIMEDEUVIMED entdecken
Crossref

Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge

Maged K Elsayad iD, Abdulsalam M Kassem iD, Elsaied H Barakat iD, Walid Anwar iD, Ayman Salama iD, Eman A Bseiso iD

Journal of Pharmacy and Pharmacology · 2026

DOI: 10.1093/jpp/rgaf103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Maged K Elsayad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Nasr City 11751, Cairo, Egypt. Hauptthemen laut MEDLINE: Dabigatran, Polymethacrylic Acids, Antithrombins. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Dabigatran etexilate (DAB), a direct thrombin inhibitor, exhibits limited oral bioavailability (6%–7%), mostly attributable to pH-dependent solubility. To address this issue, Eudragit S100 (EU)-coated liposomes were engineered to safeguard DAB-loaded nanocarriers in the stomach and provide targeted release in the intestine, where absorption occurs through several mechanisms.

Methods

Liposomal vesicles were prepared using the conventional thin film hydration method. The developed formulations were subjected to physicochemical characterization, which included Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), zeta potential analysis, particle size measurement, polydispersity index (PDI) assessment, entrapment efficiency (EE%), and transmission electron microscopy (TEM). Key findings The selected formulation, EU@DAB-Lip4, exhibited advantageous properties: minimal particle size (136.9 nm), high EE (92.67%), and colloidal stability (zeta potential −17.3 mV). In vitro release demonstrated pH-responsive behaviour, with low gastric release (12.8% at 2 hr) and enhanced intestinal release (75.5% at pH 7.4). Pharmacokinetic studies in rats demonstrated a 5.6-fold and 2.7-fold enhancement in bioavailability for EU@DAB-Lip4 relative to DAB-Lip and DAB suspension, respectively, as indicated by elevated Cmax (2664 vs. 891 and 554 ng/ml) and AUC₀−∞ (21 020 vs. 7236 and 3749 ng.hr/ml).

Conclusions

EU-coated liposomes constitute a viable platform for enhancing DAB bioavailability and therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DabigatranPolymethacrylic AcidsAntithrombinsBiological AvailabilityAnimalsLiposomesHydrogen-Ion ConcentrationAdministration, OralRatsParticle SizeMaleDrug LiberationSolubilityDrug CarriersRats, Sprague-Dawley

Stichwörter der Autor:innen

Eudragit S100dabigatran etexilateliposomesnanocarriersoral bioavailabilitypH-sensitive delivery

Substanzen

LiposomesDabigatranmethylmethacrylate-methacrylic acid copolymerPolymethacrylic AcidsDrug CarriersAntithrombins

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Nasr City 11751, Cairo, Egypt.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Menoufia National University, 70 km Cairo-Alexandria Agricultural Road, Menofia, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia.
  • Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Sixth of October City 12585, Central Axis- Part 1/1- Behind Sixth of October City Authority, Giza, Egypt.

ORCID-Profile: Maged K Elsayad, Abdulsalam M Kassem, Elsaied H Barakat, Walid Anwar, Ayman Salama, Eman A Bseiso

Zitieren

APA

Elsayad, M. K., Kassem, A. M., Barakat, E. H., Anwar, W., Salama, A., & Bseiso, E. A. (2026). Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf103

Vancouver

Elsayad MK, Kassem AM, Barakat EH, Anwar W, Salama A, Bseiso EA. Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf103

BibTeX
@article{Elsayad2026,
  author = {Elsayad, Maged K and Kassem, Abdulsalam M and Barakat, Elsaied H and Anwar, Walid and Salama, Ayman and Bseiso, Eman A},
  title = {Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  doi = {10.1093/jpp/rgaf103}
}
Kostenlos starten →